Status:
COMPLETED
Biomarkers in Samples From Patients With Follicular Lymphoma Treated With Rituximab
Lead Sponsor:
Eastern Cooperative Oncology Group
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Lymphoma
Eligibility:
All Genders
18-120 years
Brief Summary
RATIONALE: Studying the effects of rituximab in blood and tumor tissue samples from patients with cancer in the laboratory may help doctors learn more about the effects of rituximab on cancer cells. I...
Detailed Description
OBJECTIVES: * Correlate immunoglobulin Fc receptor (FcγR) polymorphisms with response, response duration, and time to resistance in samples from patients with follicular lymphoma (FL) treated with si...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosed with follicular lymphoma
- Treated on ECOG-E4402 comprising 1 of 2 different rituximab-dose strategies
- Banked peripheral blood mononuclear cells (PBMCs) and formalin-fixed paraffin-embedded (FFPE) tumor samples available
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
December 6 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 6 2011
Estimated Enrollment :
559 Patients enrolled
Trial Details
Trial ID
NCT01150643
Start Date
December 6 2010
End Date
January 6 2011
Last Update
May 17 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.